REG - Sareum Holdings PLC - Initiation of Toxicology Studies for SDC-1801

Sareum HoldingsAnnouncement

29/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250529:nRSc4896Ka&default-theme=true

RNS Number : 4896K  Sareum Holdings PLC  29 May 2025

Sareum Holdings PLC

("Sareum" or the "Company")

Initiation of Toxicology Studies for Lead TYK2/JAK1 Inhibitor, SDC-1801

Cambridge, UK, 29 May 2025 - Sareum Holdings plc (AIM: SAR), a
clinical-stage biotechnology company developing next-generation kinase
inhibitors for autoimmune disease and cancer, is pleased to announce the
initiation of a programme of toxicology studies for its lead TYK2/JAK1
inhibitor, SDC-1801.

The studies, designed to support longer-term dosing of SDC-1801, will
investigate the general toxicology and potential of SDC-1801 to interact with
other drugs. These are key regulatory requirements ahead of the planned Phase
2 clinical development programme, which is expected to focus initially on
psoriasis. This marks an important step in advancing Sareum's autoimmune
pipeline, following the successful completion of its Phase 1 clinical trial in
healthy volunteers, which demonstrated a favourable safety and pharmacokinetic
profile.

The toxicology studies required to prepare for Phase 2 clinical trials are
being conducted at an established Contract Research Organisation and are
expected to complete in Q4 2025. Sareum continues to make progress, in
parallel, with its manufacturing and formulation optimisation activities to
support the next stages of development.

Dr Stephen Parker, Executive Chairman of Sareum, commented: "We are pleased to
have initiated this important package of toxicology studies for SDC-1801,
which represents a significant milestone in the regulatory pathway towards
Phase 2 trials. This progress reflects the encouraging data generated in our
Phase 1 trial and our confidence in the potential of SDC-1801 as a
differentiated treatment for autoimmune diseases. We look forward to providing
further updates as we continue to advance this promising candidate."

 

- ENDS-

For further information, please contact:

 Sareum Holdings plc

 Stephen Parker, Executive Chairman         01223 497700

                                            ir@sareum.co.uk
 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                020 7409 3494

 Oberon Capital (Joint Broker)

 Mike Seabrook / Nick Lovering              020 3179 5300

 Hybridan LLP (Joint Broker)

 Claire Noyce                               020 3764 2341

 ICR Healthcare (Financial PR)

 Jessica Hodgson / Davide Salvi             020 3709 5700

 

About Sareum

Sareum (AIM: SAR) is a biotechnology company developing next generation kinase
inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases, with a planned
initial focus on psoriasis.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential
application for cancer immunotherapy.

The Company has recently acquired the license for SRA737, a clinical-stage
Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA
damage repair mechanisms.

Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market
of the London Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at www.sareum.com
(http://www.sareum.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFFRERITFIE